Biotechnology powerhouse AstraZeneca has inked a landmark licensing agreement with China’s CSPC Pharmaceutical Group Ltd., potentially worth $18.5 billion, aimed at developing and commercializing weight-loss and type 2 diabetes therapies globally, the companies announced Friday.

The deal marks a significant move in Western pharmaceutical investment in China and highlights the growing global race for obesity treatments.

Deal Terms and Milestones

Under the agreement, CSPC grants AstraZeneca an exclusive license to develop, manufacture, and sell the drugs worldwide, excluding China, Taiwan, Hong Kong, and Macau. AstraZeneca will pay $1.2 billion upfront, with up to $3.5 billion tied to research and development milestones, and up to $13.8 billion contingent on global sales performance. CSPC will also receive royalties on commercialized products.

The deal covers eight drug programs, including monthly injectable therapies for obesity and type 2 diabetes. Among these programs, one asset is ready for clinical trials, another is set for phase-one trials, and three additional programs are still in preclinical development.

Strategic and Scientific Implications

“This is an important step in creating a portfolio of simple, scalable, and sustainable options that can help people with obesity,” said Sharon Barr, AstraZeneca’s executive vice president. She emphasized that the new programs complement AstraZeneca’s existing pipeline.

CSPC Chair Dongchen Cai called the collaboration a “win-win” that leverages CSPC’s proprietary technology and AstraZeneca’s global capabilities to deliver next-generation treatments. Notably, AstraZeneca gains access to CSPC’s proprietary monthly dosing and delivery technology, which allows patients to self-administer the therapy independently.

Obesity affects nearly three billion people worldwide, highlighting the enormous potential market for these therapies, the companies said.

Regulatory and Market Context

The transaction requires regulatory clearance, though the companies did not specify the jurisdictions. Both parties expect the deal to close by June 2026.

Dan Coatsworth, head of markets at AJ Bell, said, “AstraZeneca is a giant in the world of medicines, and it makes sense for it to turn up the dial on weight-loss drug developments.” Shares of AstraZeneca, listed on the FTSE in London and Nasdaq, were flat in Friday morning trading.

The announcement coincides with UK Prime Minister Keir Starmer’s visit to China, during which agreements on visas, energy, and healthcare were reached. AstraZeneca separately committed $15 billion to expand manufacturing and R&D in China over four years.